Duloxetine compared with placebo for the treatment of women with mixed urinary incontinence

被引:31
作者
Bent, Alfred E. [2 ]
Gousse, Angelo E. [3 ]
Hendrix, Susan L. [4 ]
Klutke, Carl G. [5 ]
Monga, Ash K. [6 ]
Yuen, Chui K. [7 ]
Muram, David [1 ]
Yalcin, Ilker [1 ]
Bump, Richard C. [1 ]
机构
[1] Lilly Res Labs, Indianapolis, IN 46285 USA
[2] Greater Baltimore Med Ctr, Baltimore, MD USA
[3] Univ Miami, Miami, FL 33152 USA
[4] Wayne State Univ, Detroit, MI USA
[5] Washington Univ, St Louis, MO USA
[6] Princess Anne Hosp, Southampton, Hants, England
[7] Manitoba Clin, Winnipeg, MB, Canada
关键词
duloxetine; mixed urinary incontinence; stress urinary incontinence; urge urinary incontinence;
D O I
10.1002/nau.20471
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Aims: Evaluate duloxetine in the treatment of women with mixed urinary incontinence (MUI). Materials and Methods: 588 women, 19-85 years old. with > 4 incontinence episodes/week were randomly assigned to duloxetine 80 mg/day (N = 300) or placebo (N 288). Patients were classified into three symptom subgroups: stress or urge predominant MUI (SPMUI or UPMUI) or balanced MUI (BMUI) based on their responses to the validated Stress/ Urge Incontinence Questionnaire. Half the population was randomly assigned to have urodynamics; SPMUI, UPMUI, and BMUI condition diagnoses were based on signs, symptoms, and urodynamic observations. The primary outcome measure was the change in incontinence episode frequency (IEF). Secondary outcome measures included the Incontinence Quality of Life (I-QOL) scores, the ICI Quality of Life (ICIQ-SF) score, and the Patient Global Impression of Improvement (PGI-I) rating. Results: At baseline, women with SPMUI averaged 15.9 IEF/week (61% stress), those with UPMUI averaged 13.2 (70% urge), and those with BMUI averaged 16.5 (52% urge). Overall IEF decreases were significantly greater with duloxetine than placebo (median percent reduction 60% vs. 47%, P < 0.001); both UUI and SUI episodes were significantly decreased with duloxetine (median SUI IEF reduction 59% vs. 43%, P = 0.001; UUI IEF reduction 58% vs. 40%, P < 0.001.). Duloxetine IEF decreases were significantly greater for patients with SPMUI conditions and symptoms and for those with UPMUI conditions but not symptoms. Significant benefits were also demonstrated with duloxetine for improvements in I-QOL total score (11.5 points vs. 8.1 points, P = 0.002), all three I-QOL subscale scores, and for the ICIQ-SF score (-2.6 vs. -1.7, P = 0.002) as well as for PGI-I ratings (much/very much better 44.2% vs. 27.3%, P=0.001). Conclusion: Duloxetine demonstrated significant efficacy in this population of women with MUI.
引用
收藏
页码:212 / 221
页数:10
相关论文
共 28 条
[1]  
Abrams P, 2002, NEUROUROL URODYNAM, V21, P167, DOI 10.1002/nau.10052
[2]   ICIQ: A brief and robust measure for evaluating the symptoms and impact of urinary incontinence [J].
Avery, K ;
Donovan, J ;
Peters, TJ ;
Shaw, C ;
Gotoh, M ;
Abrams, P .
NEUROUROLOGY AND URODYNAMICS, 2004, 23 (04) :322-330
[3]   Validation of a two-item quantitative questionnaire for the triage of women with urinary incontinence [J].
Bent, AE ;
Gousse, AE ;
Hendrix, SL ;
Klutke, CG ;
Monga, AK ;
Yuen, CK ;
Meadows, ES ;
Yalcin, R ;
Muram, D .
OBSTETRICS AND GYNECOLOGY, 2005, 106 (04) :767-773
[4]   Pharmacological treatment of women awaiting surgery for stress urinary incontinence [J].
Cardozo, L ;
Drutz, HP ;
Baygani, SK ;
Bump, RC .
OBSTETRICS AND GYNECOLOGY, 2004, 104 (03) :511-519
[5]  
CASTRODIAZ D, 2007, IN PRESS INT J 1212
[6]   Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence [J].
Dmochowski, RR ;
Sand, PK ;
Zinner, NR ;
Gittelman, MC ;
Davila, GW ;
Sanders, SW .
UROLOGY, 2003, 62 (02) :237-242
[7]   Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence [J].
Dmochowski, RR ;
Miklos, JR ;
Norton, PA ;
Zinner, NR ;
Yalcin, I ;
Bump, RC .
JOURNAL OF UROLOGY, 2003, 170 (04) :1259-1263
[8]   Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence [J].
Dmochowski, RR ;
Davila, GW ;
Zinner, NR ;
Gittelman, MC ;
Saltzstein, DR ;
Lyttle, S ;
Sanders, SW .
JOURNAL OF UROLOGY, 2002, 168 (02) :580-586
[9]   A randomized controlled trial of duloxetine alone, pelvic floor muscle training alone, combined treatment and no active treatment in women with stress urinary incontinence [J].
Ghoniem, GM ;
Van Leeuwen, JS ;
Elser, DM ;
Freeman, RM ;
Zhao, YD ;
Yalcin, I ;
Bump, RC .
JOURNAL OF UROLOGY, 2005, 173 (05) :1647-1653
[10]   Definition of overactive bladder and epidemiology of urinary incontinence [J].
Hampel, C ;
Wienhold, D ;
Benken, N ;
Eggersmann, C ;
Thuroff, JW .
UROLOGY, 1997, 50 (6A) :4-14